SCHEMBL18763439

SCHEMBL18763439

Clc1cc(OCCCN2CCOCC2)ccc1I

nearest known ligand 0.67

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 4/20 0.67
▸ KDM4E B2RXH2 2/20 0.67
▸ HRH3 Q9Y5N1 6/20 0.59
▸ MAPK1 P28482 2/20 0.59
▸ SIGMAR1 Q99720 2/20 0.59
▸ CYP1A2 P05177 1/20 0.59
▸ CHRM2 P08172 1/20 0.59
▸ CHRM1 P11229 1/20 0.59
▸ HTR2A P28223 1/20 0.59
▸ SCN1A P35498 1/20 0.59
▸ HTR2B P41595 1/20 0.59
▸ KCNH2 Q12809 1/20 0.59
▸ SCN2A Q99250 1/20 0.59
▸ SCN3A Q9NY46 1/20 0.59
▸ NPC1 O15118 1/20 0.59
▸ USP2 O75604 1/20 0.58
▸ LMNA P02545 1/20 0.58
▸ HRH2 P25021 1/20 0.52
▸ HRH1 P35367 1/20 0.52
▸ HTT P42858 1/20 0.52

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18763475 0.84 HRH3 (0.59) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL4653076 0.80 HRH3 (0.74) ALDH1A1HRH3MAPK1SIGMAR1CYP1A2
SCHEMBL14494721 0.78 ALDH1A1 (0.65) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL214005 0.77 KDM4E (0.77) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL15260249 0.77 ALDH1A1 (0.57) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL10207398 0.76 ALDH1A1 (0.68) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL6463317 0.76 GRM4 (0.58) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL18763453 0.76 ALDH1A1 (0.55) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
SCHEMBL16314629 0.76 HRH3 (0.68) ALDH1A1KDM4EHRH3MAPK1SIGMAR1
Pramoxine SCHEMBL26020 0.75 ALDH1A1 (1.00) ALDH1A1HRH3MAPK1SIGMAR1CYP1A2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3169671-B1 1-(5-(TERT.-BUTYL)ISOXAZOL-3-YL)-3-(4-((PHENYL)ETHYNYL)PHENYL)UREA DERIVATIVES AND RELATED COMPOUNDS AS FLT3 INHIBITORS FOR TREATING CANCER SUNSHINE LAKE PHARMA CO LTD (CN) 2019-08-21 — — EP disclosed
US-10065934-B2 Substituted urea derivatives and pharmaceutical uses thereof SUNSHINE LAKE PHARMA CO., LTD. (CN) 2018-09-04 — — US disclosed
US-20170114032-A1 SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF SUNSHINE LAKE PHARMA CO., LTD. (CN) 2017-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20170114032-A1 SUBSTITUTED UREA DERIVATIVES AND PHARMACEUTICAL USES THEREOF ULK2, ULK3, ULK1 ALDH1A1 2900/4885KDM4E 2494/4885HRH3 3059/4885
US-10065934-B2 Substituted urea derivatives and pharmaceutical uses thereof ULK2, ULK3, ULK1 ALDH1A1 2900/4885KDM4E 2494/4885HRH3 3059/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback